



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, India.
Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated: May 18, 2022

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir,

We refer to the Audited financial results for the fourth quarter and Financial year ended on March 31, 2022, submitted to you today i.e., on May 18, 2022.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the press release in this regard.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

T. Chaitanya
**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**



Press Release

for Immediate Release

Granules India reports Income from operations at INR 1,030 Cr up 29% YoY, EBITDA at INR 193 Cr, EBITDA Margin at 19%; PAT at INR 111 Cr.

Hyderabad, India, May 18, 2022: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and year ended March 31, 2022.

Financial Summary (All numbers in INR Cr., except Margins)

CONSOLIDATED FINANCIALS	Q4FY22	Q3FY22	Growth (QoQ)	Q4FY21	Growth (YoY)
Income from Operations	1,030	997	3%	799	29%
EBITDA	193	174	11%	202	(5%)
EBITDA %	19%	17%		25%	
PAT	111	101	10%	128	(13%)
Net Profit Margin	11%	10%		16%	

CONSOLIDATED FINANCIALS	FY22	FY21	Growth (YoY)
Income from Operations	3,765	3,238	16%
EBITDA	722	855	(16%)
EBITDA %	19%	26%	
PAT	413	550	(25%)
Net Profit Margin	11%	17%	

Financial and Business Summary for Q4FY22 and FY22

- The Board of Directors have recommended final dividend of 75 paise per equity share of Re.1/- each in addition to interim dividend of 75 paise per equity share of Re.1/- each paid during the year.
- Revenue for Q4FY22 stood at INR 1,030Cr, growth of 29% YoY across all geographies and segments. Revenue share from Europe increased to 21.5% when compared to 14.5% YoY.
- Increase in Revenue, EBITDA and PAT in Q4FY22 compared to Q3FY22, despite adverse business condition arising out of supply constraints of Para Amino Phenol (PAP), other input price cost increase and logistic cost increase.
- Revenue share of non-core molecules stood at 19% on a full year basis versus 16% in the previous year, in line with our long-term strategy
- During the quarter we filed one ANDA, two US DMF, and received two ANDA approvals.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “FY 22 has been a challenging year for the industry in the face of adverse external environment with headwinds around the availability and price for Raw Materials, Solvents, Catalysts, uncertainties arising out of Ukraine-Russia conflict as well as re-emergence of Covid cases in China. The global supply chain and logistics continue to remain under duress. In face of these challenges, Granules has demonstrated great resilience and I am happy with the performance of the Company. While we strive for continued improvement in our financial performance in the short term, we are working on long term strategy for making ourselves self-sustainable and overcome most of the challenges that we are facing now. We are now embarking on a new journey to reimagine our business model and transform Granules to an Innovative, science & technology driven organization, with responsible sustainable operations.”

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, US and UK The Company has 7 manufacturing facilities out of which 6 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:	
Krishna Raghunathan 040-69043573 VP – Finance and Investor Relations krishna.raghunathan@granulesindia.com	Chaitanya Tummala 040-69043614 Company Secretary chaitanya.tummala@granulesindia.com